Holen Sie sich die Stockscreener-App
23.09
3.64%
0.81
Handel nachbörslich:
22.94
-0.15
-0.65%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$22.28
Offen:
$22.23
24-Stunden-Volumen:
77.33M
Relative Volume:
1.59
Marktkapitalisierung:
$135.71B
Einnahmen:
$62.46B
Nettoeinkommen (Verlust:
$7.88B
KGV:
16.73
EPS:
1.38
Netto-Cashflow:
$11.22B
1W Leistung:
-3.27%
1M Leistung:
+5.39%
6M Leistung:
-11.84%
1J Leistung:
-17.57%
1-Tages-Spanne:
$22.18
$23.15
1-Wochen-Bereich:
$22.18
$23.89
52-Wochen-Spanne:
$20.91
$31.54
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Vergleichen Sie PFE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
23.09 | 135.71B | 62.46B | 7.88B | 11.22B | 1.38 |
|
LLY
Lilly Eli Co
|
755.57 | 737.45B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
154.14 | 372.94B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
190.07 | 346.84B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
67.74 | 307.13B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
NVS
Novartis Ag Adr
|
108.95 | 223.34B | 53.22B | 12.86B | 14.85B | 6.39 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
What has Trump said about cutting drug prices? - marketscreener.com
Pfizer, Merck, Johnson & Johnson to lose billions to Trump's latest executive order - TheStreet
Pfizer, Eli Lilly, Merck Stock Turns Around on Trump Drug Pricing Executive Order - Barron's
US Pharma stocks Pfizer, Amgen, Merck & Co. jump over 3% on early Wall Street after Trump cut drug prices - Mint
Zacks Market Edge Highlights: WHR, PFE, CVX, CC and DOW - TradingView
Shareholders Will Be Pleased With The Quality of Pfizer's (NYSE:PFE) Earnings - Yahoo Finance
Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket - Benzinga
Faruqi & Faruqi Reminds Cerevel Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 3, 2025 - GlobeNewswire Inc.
Aminoglycosides Market Growth, Trends & Forecast 2025 | Top key - openPR.com
Pfizer’s $15 Billion War Chest: What Will They Buy After the Danuglipron Failure? - Smartkarma
Is Pfizer Inc. (PFE) the Best High-Yield Dividend Stock for 2025 and Beyond? - Insider Monkey
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Is Pfizer Stock A Buy Or A Sell On Its Massive Savings Plan? - Investor's Business Daily
Are Your Mega-High Stock Dividends Safe? - TradingView
Pfizer (NYSE:PFE) Hasn't Been This Cheap in 13 Years. Time to Buy? - 24/7 Wall St.
Pfizer (PFE) Just Overtook the 20-Day Moving Average - Yahoo Finance
Was Jim Cramer Right About Pfizer (PFE)? - Yahoo Finance
Lilly shuffles key executive positions; Mikael Dolsten takes another post-Pfizer assignment - Endpoints News
Layoff Tracker: Shape, Vor Cut Workforces - BioSpace
If You Invested $10K In Pfizer Stock 10 Years Ago, How Much Would You Have Now? - Yahoo Finance
Chronic Pelvic Pain Treatment Market Is Booming Worldwide 2025-2032 | Pfizer Inc., Johnson & Johnson, AbbVie Inc. - openPR.com
Pfizer Sues Alkem to Block Copies of Xeljanz XR Arthritis Drug - Bloomberg Law News
Can Pfizer (PFE) Climb 25.14% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
Pfizer Inc. (NYSE:PFE) Q1 2025 Earnings Call Transcript - MSN
The Mindfulness of Medicine Development: How Scientists Are Driving the Next Wave of Medical Innovations - Pfizer
Jim Cramer on Pfizer (PFE): “Trying Big Targets, but New Wins Still Elusive” - Insider Monkey
US FDA advisers to discuss COVID-19 vaccine recommendations on May 22 - marketscreener.com
Generic Oncology Drugs Market Size Estimated to Reach USD 30,998 Mn by 2034, Rising Global Cancer Cases Increase Demand for Affordable Treatments - GlobeNewswire Inc.
Pfizer (PFE) Awaits FDA Panel Review of Cancer Drug Combination - GuruFocus
Pfizer, J&J, Genentech drugs subject of FDA advisory panel meeting this month - Seeking Alpha
Ex-Dividend Reminder: American Electric Power, Pfizer and Tompkins Financial - Nasdaq
Pharma imports to US surged in March as drugmakers look to avoid tariffs - marketscreener.com
Trump Sets Pharma Tariffs Deadline. The Fallout for Lilly, Pfizer, Other Drugmakers. - Barron's
Pfizer (PFE) RSV Vaccine Recommendations Under Review - GuruFocus
Pfizer, GSK RSV shot recommendations under scrutiny from RFK Jr. aidereport - Seeking Alpha
PFE Stock Price: Pfizer Inc Named Top Dividend Stock as Insider Buying Surges, Yield Hits 7.21% - paginasiete.bo
Pfizer Has Unreasonable Whiff Of The Marlboro Man - Seeking Alpha
Pfizer Named Top Dividend Stock With Insider Buying and 7.21% Yield (PFE) - Nasdaq
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cerevel Therapeutics - TradingView
Here's Why We're Wary Of Buying Pfizer's (NYSE:PFE) For Its Upcoming Dividend - simplywall.st
Do These 3 Checks Before Buying Pfizer Inc. (NYSE:PFE) For Its Upcoming Dividend - Yahoo Finance
Recombinant Human Endostatin Market Top PlayersPfizer Inc., - openPR.com
April Social Media Round-Up—Webby Award, World Immunization Week, and More - Pfizer
Pfizer Stock Up 5% Following Q1 Results: Time To Buy, Sell Or Hold? - Barchart.com
Analyst recommendations: Amazon, PepsiCo, Linde, Pfizer, Crowdstrike Holdings... - marketscreener.com
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Sirolimus Market Is Booming Worldwide 2025-2032 | Pfizer Inc., Actiza, Zydus Cadila Healthcare Ltd. - openPR.com
Pfizer Stock Up 5% Following Q1 Results: Time to Buy, Sell or Hold? - Nasdaq
Anti Suicide Drugs Market Detailed In New Research Report 2025 | - openPR.com
Is Pfizer Inc. (PFE) The Most Profitable Cheap Stock to Buy Now? - Insider Monkey
Is Pfizer Inc.'s (NYSE:PFE) Stock Price Struggling As A Result Of Its Mixed Financials? - Yahoo Finance
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.32%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):